CSIMarket



Dyne Therapeutics Inc   (DYN)
Other Ticker:  
 
 

DYN's Net Cash Flow Growth by Quarter and Year

Dyne Therapeutics Inc 's Net Cash Flow results by quarter and year




DYN Net Cash Flow (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December - -28.21 -76.45 -
III Quarter September - -29.34 364.97 -
II Quarter June - -52.56 - 318.00
I Quarter March -52.86 10.48 - 316.00
FY   -52.86 -99.63 288.52 634.00



DYN Net Cash Flow first quarter 2022 Y/Y Growth Comment
Dyne Therapeutics Inc in the first quarter 2022 recorded net cash outflow of $ -52.86 millions.

According to the results reported in the first quarter 2022, Dyne Therapeutics Inc achieved the best Net Cash Flow growth in Biotechnology & Pharmaceuticals industry. While Dyne Therapeutics Inc ' s Net Cash Flow no change of % ranks overall at the positon no. in the first quarter 2022.




DYN Net Cash Flow ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - -54.49 % -

Financial Statements
Dyne Therapeutics Inc 's first quarter 2022 Net Cash Flow $ -52.86 millions DYN's Income Statement
Dyne Therapeutics Inc 's first quarter 2021 Net Cash Flow $ 10.48 millions Quarterly DYN's Income Statement
New: More DYN's historic Net Cash Flow Growth >>


DYN Net Cash Flow (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - 0.63 %
I Quarter March - - - -1.56 %
FY (Year on Year)   - - -54.49 % -




Net Cash Flow first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Net Cash Flow Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Net Cash Flow first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Net Cash Flow Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Net Cash Flow by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Dyne Therapeutics Inc 's Q/Q Net Cash Flow Growth


Net Cash Flow Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


DYN's I. Quarter Q/Q Net Cash Flow Comment
Recent results of -52.86 millions by Dyne Therapeutics Inc appear even worse compare to the net cash outflow -28.21 millions in the forth quarter.

Within Biotechnology & Pharmaceuticals industry Dyne Therapeutics Inc achieved highest sequential Net Cash Flow growth. While Dyne Therapeutics Inc 's Net Cash Flow growth quarter on quarter, overall rank is .


Net Cash Flow Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Net Cash Flow Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Net Cash Flow Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


DYN's I. Quarter Q/Q Net Cash Flow Comment
I. Quarter 2022 accomplishment of -52.86 millions by Dyne Therapeutics Inc appear even less good compare to the net cash outflow -28.21 millions a quarter before.

Within Biotechnology & Pharmaceuticals industry Dyne Therapeutics Inc achieved highest sequential Net Cash Flow growth. While Dyne Therapeutics Inc 's Net Cash Flow growth quarter on quarter, overall rank is .


Dyne Therapeutics Inc 's 12 Months Net Cash Flow Growth Year on Year


Net Cash Flow TTM Growth

12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Sep 30 2021)
12 Months Ending
(Jun 30 2021)
12 Months Ending
(Mar 31 2021)
Cumulative Net Cash Flow 12 Months Ending $ -162.97 $ -99.63 $ -147.87 $ 246.44 $ 0.00
Y / Y Net Cash Flow Growth (TTM) - - - - -
Year on Year Net Cash Flow Growth Overall Ranking # # # # #
Seqeuential Net Cash Flow Change (TTM) - - - - -
Seq. Net Cash Flow Growth (TTM) Overall Ranking # # # # #




Cumulative Net Cash Flow growth Comment
Dyne Therapeutics Inc ' has realized cumulative trailing twelve months net cash outflow of $ -163 millions in the Mar 31 2022 period.
The situation is worsening as the cumulative net cash outflow is inflating from $ -99.63 millions for the period from Dec 31 2021 to Mar 31 2021 and $ -28.21 millions for the twelve months ending in the quarter a year ago Ashton H. Walker mentioned.

Dyne Therapeutics Inc achieved highest trailing twelve month year on year Net Cash Flow growth. While overall Net Cash Flow growth ranking, remained unchanged compare to the previous quarter at no. .

Net Cash Flow TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Net Cash Flow TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Net Cash Flow TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Cash Flow TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Net Cash Flow growth Comment
Dyne Therapeutics Inc ' has realized cumulative trailing twelve months net cash outflow of $ -163 millions in the Mar 31 2022 period.
The situation is detiriorating as the cumulative net cash outflow is becoming larger from $ -99.63 millions for the period from Dec 31 2021 to Mar 31 2021 and $ -28.21 millions from the TTM period ending Mar 31 2021 Ashton H. Walker wrote.

Dyne Therapeutics Inc achieved highest trailing twelve month year on year Net Cash Flow growth. While overall Net Cash Flow growth ranking, remained unchanged compare to the previous quarter at no. .

Net Cash Flow TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Cash Flow TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Net Cash Flow TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Cash Flow TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Net Cash Flow Growth
Biotechnology & Pharmaceuticals Industry Net Cash Flow Growth Trends and Statistics
Healthcare Sector Net Cash Flow Growth Statistics
Net Cash Flow Growth Trends for overall market
DYN's Net Cash Flow Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Net Cash Flow Growth
Lowest Ranking Net Cash Flow Growth
Net Cash Flow Growth for DYN's Competitors
Net Cash Flow Growth for Dyne Therapeutics Inc 's Suppliers
Net Cash Flow Growth for DYN's Customers

You may also want to know
DYN's Annual Growth Rates DYN's Profitability Ratios DYN's Asset Turnover Ratio DYN's Dividend Growth
DYN's Roe DYN's Valuation Ratios DYN's Financial Strength Ratios DYN's Dividend Payout Ratio
DYN's Roa DYN's Inventory Turnover Ratio DYN's Growth Rates DYN's Dividend Comparisons



Companies with similar Net Cash Flow no change for the quarter ending Mar 31 2022 within Healthcare SectorY/Y Change %Net Cash Flow for the quarter ending Mar 31 2022
Aikido Pharma Inc.-3.59%$ -3.589 millions
Quidel Corporation-3.73%$ -3.732 millions
Lineage Cell Therapeutics Inc.-5.12%$ -5.116 millions
Cv Sciences Inc.-6.75%$ -6.748 millions
Tandem Diabetes Care Inc -14.05%$ -14.050 millions
Eventbrite Inc -14.36%$ -14.358 millions
Acer Therapeutics Inc.-20.21%$ -20.211 millions
Abcellera Biologics Inc -23.09%$ -23.087 millions
China Health Industries Holdings Inc -23.82%$ -23.817 millions
Cardiovascular Systems Inc -29.81%$ -29.806 millions
Aclaris Therapeutics Inc -31.89%$ -31.892 millions
Prophase Labs Inc -33.82%$ -33.816 millions
Assertio Holdings inc -38.93%$ -38.930 millions
Co diagnostics Inc.-40.49%$ -40.492 millions
International Stem Cell Corporation-46.96%$ -46.963 millions
Intra cellular Therapies Inc -47.19%$ -47.193 millions
Phibro Animal Health Corp-49.46%$ -49.461 millions
Landos Biopharma Inc -51.20%$ -51.202 millions
Plus Therapeutics Inc -53.47%$ -53.467 millions
Clearside Biomedical Inc -55.58%$ -55.576 millions
Geovax Labs Inc -55.89%$ -55.891 millions
Diversified Healthcare Trust-55.98%$ -55.979 millions
Vaccinex Inc.-56.29%$ -56.292 millions
Ridgefield Acquisition Corp-56.53%$ -56.530 millions
Conmed Corporation-57.32%$ -57.325 millions
Celsion Corporation-57.39%$ -57.389 millions
Innoviva Inc -58.03%$ -58.034 millions
Apollo Medical Holdings Inc -59.31%$ -59.306 millions
Dariohealth Corp -62.48%$ -62.484 millions
Relmada Therapeutics Inc -62.49%$ -62.485 millions


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

RGIN's Profile

Stock Price

RGIN's Financials

Business Description

Fundamentals

Charts & Quotes

RGIN's News

Suppliers

RGIN's Competitors

Customers & Markets

Economic Indicators

RGIN's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071